Artal Group’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-200,000
Closed -$5.98M 138
2022
Q1
$5.98M Hold
200,000
0.25% 71
2021
Q4
$6.85M Hold
200,000
0.19% 86
2021
Q3
$7.41M Hold
200,000
0.17% 95
2021
Q2
$7.81M Hold
200,000
0.16% 104
2021
Q1
$8.51M Buy
+200,000
New +$8.9M 0.15% 105

Other funds holding IMCR

Artal Group's IMCR Position: Q2 2022 in Review

Artal Group sold out of Immunocore (IMCR) in Q2 2022, closing a stake of 200,000 shares — an estimated $5.98M sold.

Artal Group first reported a position in IMCR in Q1 2021 and held it in 5 quarters. The position peaked at $8.51M in Q1 2021. 66 funds tracked by Wall St. Rank hold IMCR as of Q2 2022.

  • Artal Group reported no remaining Immunocore position as of Q2 2022 after selling out during the quarter.
  • Artal Group sold 200,000 Immunocore shares in Q2 2022, an estimated $5.98M.
  • Artal Group first reported a position in Immunocore in Q1 2021 and held it in 5 quarters.
  • Artal Group's Immunocore position peaked at $8.51M in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Immunocore as of Q2 2022.

Based on Artal Group's 13F filing for Q2 2022, filed 11 Aug 2022.